Generated by AI
Celldex Therapeutics Inc. is a biopharmaceutical company focused on developing antibody-based therapies for severe inflammatory, allergic, and autoimmune diseases. The company’s current programs center on monoclonal and bispecific antibodies designed to modulate mast cell biology and other immune pathways associated with chronic conditions that have limited treatment options. Its lead clinical assets include barzolvolimab, a KIT-targeting antibody being studied across several mast cell–driven disorders, and CDX-622, a bispecific candidate aimed at key inflammatory mechanisms. Celldex Therapeutics Inc. operates in the biotechnology sector and concentrates on advancing immunology-focused therapies through clinical development for patients with significant unmet medical needs. Headquartered in Hampton, New Jersey, the company is known for its specialized pipeline rather than a broad commercial product portfolio.
WebsitePerryville III Building
Hampton, NJ, 08827
United States
The latest articles about CLDX.
Celldex Therapeutics reported third quarter 2026 results with a net loss of US$75.56 million and basic loss per share of US$0.96, alongside a universal shelf registration covering common and preferred stock, warrants, depositary shares and units. The combination of widening losses and a fresh universal shelf registration highlights the pressure on Celldex Therapeutics to secure funding while it continues to invest heavily in its antibody pipeline without meaningful current revenue. We will...
Summary of Sep 23's posts. Generated by AI.
Summary of Sep 25's posts. Generated by AI.
Summary of Mar 8's posts. Generated by AI.
Summary of Sep 22's posts. Generated by AI.
Investors talking about CLDX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.